Bionomics Investor Presentation Deck

BNC210 Addresses the Shortcomings of Existing Social Anxiety Disorder Approaches Novel Mechanism of Action Bionomics Attractive Clinical & Regulatory Pathway Anti-Anxiety Effects BNC 210 Potential for Acute Treatment in Social Anxiety Disorder Patients 1. 2. Rapid Onset of Action Unique Formulation Attributes CURRENT TREATMENTS FOR SOCIAL ANXIETY DISORDER NO NO NO WITHDRAWAL MEMORY MOTOR SYNDROME IMPAIRMENT IMPAIRMENT X X X DRUG Benzodiazepines 2 DRUG FAST ACTING ✔ SSRIs/SNRIS X ✔ X ✔ BNC210 BNC210 IS DESIGNED TO PROVIDE ADVANTAGES COMPARED TO CURRENT THERAPIES* NO SEDATION X FAST ACTING ✔ NO SEDATION ✔ * Potential benefits based on analysis of data from separate studies and not on results that might have been obtained from head-to-head studies. Such data may not be directly comparable due to differences in study protocols, conditions and patient populations. Accordingly, cross-trial comparisons may not be reliable predictors of the relative efficacy or other benefits of BNC210 compared to existing therapies or other product candidates that may be approved or are in development for the treatment of PTSD or SAD. Includes Valium and certain other benzodiazepines Includes Prozac and certain other SSRIs (Selective Serotonin Reuptake Inhibitors) /SNRIS (Serotonin-Norepinephrine Reuptake Inhibitors) ✔ NO NO NO WITHDRAWAL MEMORY MOTOR SYNDROME IMPAIRMENT IMPAIRMENT E ✔ ✔ 11

View entire presentation